139 related articles for article (PubMed ID: 22913768)
1. Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice.
Weycker D; Danel A; Marciniak A; Bendall K; Lipsitz M; Pettengell R
BMC Cancer; 2012 Aug; 12():362. PubMed ID: 22913768
[TBL] [Abstract][Full Text] [Related]
2. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
[TBL] [Abstract][Full Text] [Related]
3. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
4. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Sutheesophon J; Sutcharitchan P; Swasdikul D
Leuk Lymphoma; 2000 Apr; 37(3-4):351-60. PubMed ID: 10752986
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Yokoyama M; Kusano Y; Takahashi A; Inoue N; Ueda K; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
Support Care Cancer; 2017 Nov; 25(11):3313-3320. PubMed ID: 28551843
[TBL] [Abstract][Full Text] [Related]
6. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
Morrison VA; Picozzi V; Scott S; Pohlman B; Dickman E; Lee M; Lawless G; Kerr R; Caggiano V; Delgado D; Fridman M; Ford J; Carter WB;
Clin Lymphoma; 2001 Jun; 2(1):47-56. PubMed ID: 11707870
[TBL] [Abstract][Full Text] [Related]
7. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
8. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.
Li S; Liu J; Bowers C; Garawin TAFS; Kim C; Bensink ME; Chandler DB
Support Care Cancer; 2020 Jan; 28(1):113-122. PubMed ID: 30993450
[TBL] [Abstract][Full Text] [Related]
9. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
[TBL] [Abstract][Full Text] [Related]
10. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
11. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
Scott SD; Chrischilles EA; Link BK; Delgado DJ; Fridman M; Stolshek BS
J Manag Care Pharm; 2003; 9(2 Suppl):15-21. PubMed ID: 14613340
[TBL] [Abstract][Full Text] [Related]
12. Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis.
Pettengell R; Schwenkglenks M; Bacon P; Lawrinson S; Duehrsen U
Hematol Oncol; 2011 Dec; 29(4):177-84. PubMed ID: 21246591
[TBL] [Abstract][Full Text] [Related]
13. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma.
Chrischilles E; Delgado DJ; Stolshek BS; Lawless G; Fridman M; Carter WB
Cancer Control; 2002; 9(3):203-11. PubMed ID: 12060818
[TBL] [Abstract][Full Text] [Related]
14. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.
Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
Curr Med Res Opin; 2017 Dec; 33(12):2107-2113. PubMed ID: 28958157
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
[TBL] [Abstract][Full Text] [Related]
16. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims.
Weycker D; Hanau A; Lonshteyn A; Bowers C; Bensink M; Garawin T; Chandler D
Curr Med Res Opin; 2018 Sep; 34(9):1705-1711. PubMed ID: 29962268
[TBL] [Abstract][Full Text] [Related]
17. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.
Souêtre E; Qing W
Pharmacoeconomics; 1994; 6 Suppl 2():36-43. PubMed ID: 10172484
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
Lyman G; Lalla A; Barron R; Dubois RW
Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]